Effectiveness of Messenger RNA-based Vaccines During the Emergence of the Severe Acute Respiratory Syndrome Coronavirus 2 Omicron Variant
- PMID: 35475889
- PMCID: PMC9129111
- DOI: 10.1093/cid/ciac325
Effectiveness of Messenger RNA-based Vaccines During the Emergence of the Severe Acute Respiratory Syndrome Coronavirus 2 Omicron Variant
Abstract
Background: We evaluated the effectiveness of mRNA-based vaccines following emergence of SARS-CoV-2 Omicron variant.
Methods: Recipients of a third dose of BNT162b2 or mRNA-1273 ≥180 days after the primary series were matched to primary-series recipients and unvaccinated persons. Participants were followed from 1 December 2021 to 12 March 2022. Outcomes were documented SARS-CoV-2 infection, COVID-19 hospitalization, and COVID-19 death. Effectiveness was calculated from 100-day risks estimated with the Kaplan-Meier estimator.
Results: BNT162b2 and mRNA-1273 groups included 221 267 and 187 507 third-dose recipients, respectively, matched to equal numbers of primary-series recipients and unvaccinated persons. Compared with no vaccination, effectiveness of a third dose of BNT162b2 was 47.8% (95% confidence interval [CI], 45.2-50.3), 81.8% (95% CI, 79.2-84.2), and 89.6% (95% CI, 85.0-93.6) against infection, hospitalization, and death, respectively. Effectiveness of a third dose of BNT162b2 compared with the primary series was 30.1% (95% CI, 26.2-33.7), 61.4% (95% CI, 55.0-67.1), and 78.8% (95% CI, 67.9-87.5) against infection, hospitalization, and death, respectively. Effectiveness of a third dose of mRNA-1273 compared with no vaccination was 61.9% (95% CI, 59.4-64.4), 87.9% (95% CI, 85.3-90.2), and 91.4% (95% CI, 86.4-95.6) against infection, hospitalization, and death, respectively. Effectiveness of a third dose of mRNA-1273 compared with the primary series was 37.1% (95% CI, 32.2-41.7), 63.5% (95% CI, 53.7-71.6), and 75.0% (95% CI, 55.4-88.0) against infection, hospitalization, and death, respectively.
Conclusions: BNT162b2 and mRNA-1273 were effective against COVID-19 following emergence of Omicron variant. A third dose provided additional protection over the primary series.
Keywords: COVID-19; Omicron; epidemiology; vaccine.
Published by Oxford University Press on behalf of Infectious Diseases Society of America 2022.
Conflict of interest statement
Potential conflicts of interest. All authors: No reported conflicts of interest. All authors have submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest. Conflicts that the editors consider relevant to the content of the manuscript have been disclosed.
Similar articles
-
Effect of mRNA Vaccine Boosters against SARS-CoV-2 Omicron Infection in Qatar.N Engl J Med. 2022 May 12;386(19):1804-1816. doi: 10.1056/NEJMoa2200797. Epub 2022 Mar 9. N Engl J Med. 2022. PMID: 35263534 Free PMC article.
-
Vaccine effectiveness against SARS-CoV-2 infection or COVID-19 hospitalization with the Alpha, Delta, or Omicron SARS-CoV-2 variant: A nationwide Danish cohort study.PLoS Med. 2022 Sep 1;19(9):e1003992. doi: 10.1371/journal.pmed.1003992. eCollection 2022 Sep. PLoS Med. 2022. PMID: 36048766 Free PMC article.
-
Effectiveness of a Third Dose of mRNA Vaccines Against COVID-19-Associated Emergency Department and Urgent Care Encounters and Hospitalizations Among Adults During Periods of Delta and Omicron Variant Predominance - VISION Network, 10 States, August 2021-January 2022.MMWR Morb Mortal Wkly Rep. 2022 Jan 21;71(4):139-145. doi: 10.15585/mmwr.mm7104e3. MMWR Morb Mortal Wkly Rep. 2022. PMID: 35085224 Free PMC article.
-
BNT162b2 Vaccine Effectiveness against Omicron in Children 5 to 11 Years of Age.N Engl J Med. 2022 Jul 21;387(3):227-236. doi: 10.1056/NEJMoa2205011. Epub 2022 Jun 29. N Engl J Med. 2022. PMID: 35767475 Free PMC article.
-
Comparative analysis of the risks of hospitalisation and death associated with SARS-CoV-2 omicron (B.1.1.529) and delta (B.1.617.2) variants in England: a cohort study.Lancet. 2022 Apr 2;399(10332):1303-1312. doi: 10.1016/S0140-6736(22)00462-7. Epub 2022 Mar 16. Lancet. 2022. PMID: 35305296 Free PMC article.
Cited by
-
Effectiveness of COVID-19 Vaccine Booster Shot Compared with Non-Booster: A Meta-Analysis.Vaccines (Basel). 2022 Aug 25;10(9):1396. doi: 10.3390/vaccines10091396. Vaccines (Basel). 2022. PMID: 36146474 Free PMC article. Review.
-
Description of Hospitalizations due to the Severe Acute Respiratory Syndrome Coronavirus 2 Omicron Variant Based on Vaccination Status.Open Forum Infect Dis. 2022 Aug 25;9(9):ofac438. doi: 10.1093/ofid/ofac438. eCollection 2022 Sep. Open Forum Infect Dis. 2022. PMID: 36092825 Free PMC article.
-
Evolution of the Clinical Profile and Outcomes of Unvaccinated Patients Affected by Critical COVID-19 Pneumonia from the Pre-Vaccination to the Post-Vaccination Waves in Italy.Pathogens. 2022 Jul 14;11(7):793. doi: 10.3390/pathogens11070793. Pathogens. 2022. PMID: 35890037 Free PMC article.
LinkOut - more resources
Full Text Sources
Miscellaneous